Discovery of the active ingredients and the mechanism of action for the effects of Bufei Huoxue Capsule on pneumonia recovery based on network pharmacology methods

RAO Hongyu; CHEN Pan; LI Peibo; GUAN Minyi; SU Weiwei

doi:10.13471/j.cnki.acta.snus.2020.04.15.2020E009

您当前的位置：

首页 >

文章列表页 >

Discovery of the active ingredients and the mechanism of action for the effects of Bufei Huoxue Capsule on pneumonia recovery based on network pharmacology methods

Research articles | 更新时间：2023-11-01

- Discovery of the active ingredients and the mechanism of action for the effects of Bufei Huoxue Capsule on pneumonia recovery based on network pharmacology methods
- Acta Scientiarum Naturalium Universitatis Sunyatseni Vol. 60, Issue 4, Pages: 42-49(2021)
- 作者机构：
  
  广东省中药上市后质量与药效再评价工程技术研究中心 / 广东省热带亚热带植物资源重点实验室 / 中山大学生命科学学院，广东广州510275
- 作者简介：
- 基金信息：
- DOI：10.13471/j.cnki.acta.snus.2020.04.15.2020E009
  CLC： R285
- Published：25 July 2021，
  
  Published Online：28 October 2020，
  
  Received：15 April 2020，
  
  Accepted：09 June 2020
扫描看全文
饶鸿宇,谌攀,李沛波等.基于网络药理学探讨补肺活血胶囊用于重症肺炎患者康复期治疗的关键成分和作用机制[J].中山大学学报(自然科学版),2021,60(04):42-49.

RAO Hongyu,CHEN Pan,LI Peibo,et al.Discovery of the active ingredients and the mechanism of action for the effects of Bufei Huoxue Capsule on pneumonia recovery based on network pharmacology methods[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2021,60(04):42-49.
饶鸿宇,谌攀,李沛波等.基于网络药理学探讨补肺活血胶囊用于重症肺炎患者康复期治疗的关键成分和作用机制[J].中山大学学报(自然科学版),2021,60(04):42-49. DOI： 10.13471/j.cnki.acta.snus.2020.04.15.2020E009.

RAO Hongyu,CHEN Pan,LI Peibo,et al.Discovery of the active ingredients and the mechanism of action for the effects of Bufei Huoxue Capsule on pneumonia recovery based on network pharmacology methods[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2021,60(04):42-49. DOI： 10.13471/j.cnki.acta.snus.2020.04.15.2020E009.

摘要

运用网络药理学技术，探究了补肺活血胶囊用于重症肺炎患者康复期治疗的关键成分及作用机制，为补肺活血胶囊促进肺炎患者康复提供依据。使用TCMSP和CTD数据库检索补肺活血胶囊中化合物的作用靶点，再与SwissTargetPrediction数据库预测的潜在作用靶点进行整合，得到补肺活血胶囊成分的全部潜在靶基因。运用String 数据库进行蛋白互作分析（PPI），筛选出补肺活血胶囊的核心靶点，找到对应的化合物，并构建药材-关键成分-核心靶点网络。采用David数据库对核心靶点进行研究，明确补肺活血胶囊的作用机制。共搜集到补肺活血胶囊作用的靶点1 102个，筛选得到核心靶点215个，主要涉及AKT1、MAPK3、VEGFA、CASP3和EGFR等。KEGG通路富集得到TNF、T cell receptor、Rap1、PI3K-Akt、HIF-1和FoxO等相关信号通路，为补肺活血胶囊促进肺炎患者康复的潜在靶标通路。补肺活血胶囊能通过多靶点多通路抑制机体炎症，缓解患者的肺纤维化程度，加速恢复期患者的康复，有效地促进肺炎患者的康复。

Abstract

The study aimed to explore the mechanism of action of Bufei Huoxue Capsule （BFHXC） for treatment of pneumonia recovery through network pharmacology. The constituents of BFHXC were collected by preliminary studies. The targets of constituents were collected by TCMSP and Toxicogenomics Database （CTD） as well as by prediction of SwissTargetPrediction based on structural similarity. Protein-protein interaction （PPI） data was constructed by using String website for screening key targets. The herb-active ingredient-key target network was constructed by using Cytoscape software，followed by topology analysis. The DAVID database was used to perform GO enrichment analysis and KEGG pathway analysis on the key targets for predicting the mechanism of action of BFHXC. A total of 1 102 targets were collected for BFHXC， and 215 key targets were screened， such as AKT1， MAPK3， VEGFA， CASP3， EGFR and so on. The results of pathway enrichment indicated that TNF signaling pathway， T cell receptor signaling pathway， Rap1 signaling pathway， PI3K/Akt signaling pathway， HIF-1 signaling pathway and FoxO signaling pathway were the key pathways， which were involved in the treatment of pneumonia recovery. BFHXC may exhibit therapeutic effects on pneumonia recovery probably through inhibiting inflammation and relieving pulmonary fibrosis based on multi-target and multi-pathway.

关键词

补肺活血胶囊重症肺炎康复网络药理学

Keywords

Bufei Huoxue Capsulepneumonia recoverynetwork pharmacology

references

中国康复医学会重症康复专业委员会呼吸重症康复学组，中国老年保健医学研究会老龄健康服务与标准化分会，《中国老年保健医学》杂志编辑委员会，等. 中国呼吸重症康复治疗技术专家共识［J］. 中国老年保健医学，2018，16（5）： 3-11.

Chinese Association of Rehabilitation Medicine， Chinese Association Geriatric Research， Chinese Journal of Geriatric Care， et al. Consensus of Chinese respiratory rehabilitation technical experts［J］. Chinese Journal of Geriatric Care， 2018， 16（5）： 3-11.

安徽省中医药学会. 安徽省新型冠状病毒肺炎中医药治疗专家共识［EB/OL］. ［2020-02-17］. http：//ahszyyxh.cn/news/shownews.phphttp://ahszyyxh.cn/news/shownews.php？lang=cn&id=431.

唐清，朱晓枭，郑玉莹，等. 补肺活血胶囊中毛蕊异黄酮葡萄糖苷、毛蕊异黄酮的测定方法［J］. 中山大学学报（自然科学版），2017，56（6）： 123-127.

TANG Q， ZHU X X， ZHENG Y Y， et al. Determination of calycosin-7-O-β-D-glucoside and calycosin in Bufeihuoxue capsules by HPLC ［J］. Acta Scientiarum Naturalium Universitatis Sunyatseni， 2017， 56（6）： 123-127.

唐清，朱晓枭，郑玉莹，等. 补肺活血胶囊高效液相色谱指纹图谱研究［J］. 中南药学，2018，16（9）： 1200-1204.

TANG Q， ZHU X X， ZHENG Y Y， et al. HPLC fingerprint of Bufei Huoxue capsules ［J］. Central South Pharmacy， 2018， 16（9）： 1200-1204.

唐清，郑玉莹，关敏怡，等. 基于UFLC-Triple TOF MS/MS技术的补肺活血胶囊化学物质基础研究［J］. 中南药学，2018，16（12）： 1677-1683.

TANG Q， ZHENG Y Y， GUAN M Y， et al. Chemical material basis for Bufei Huoxue capsules by ultrafast liquid chromatography/triple time-of-flight tandem mass spectrometry［J］. Central South Pharmacy， 2018， 16（12）： 1677-1683.

李泮霖，苏薇薇. 网络药理学在中药研究中的最新应用进展［J］.中草药，2016，47（16）： 2938-2942.

LI P L， SU W W. Recent progress in applying network pharmacology to research of Chinese materia medica［J］. Chinese Traditional and Herbal Drugs， 2016， 47（16）： 2938-2942.

饶鸿宇，李沛波，谌攀，等. 基于网络药理学探讨红核妇洁洗液抗炎的活性成分和作用机制［J］.药学研究，2021，40（1）： 9-15.

RAO H Y， LI P B， CHEN P， et al. Discovery of the active ingredients and the mechanism of the action for the effects of Honghe Fujie Lotion on inflammation based on network pharmacology methods［J］. Journal of Pharmaceutical Research， 2021， 40（1）： 9-15.

JASON H T B， BRADFORD J S. Ventilator-induced lung injury and lung mechanics［J］. Annals of Translational Medicine， 2018， 6（19）：378.

NURIA E C， JOHN G L， MATTEO P， et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome： a significant contributor to poor outcome［J］. Anesthesiology， 2014， 121（1）：189-198.

ROBERT K L， CHRISTOPHER R M， RADHA K， et al. ICU early physical rehabilitation programs： financial modeling of cost savings［J］. Critical Care Medicine， 2013， 41（3）：717-724.

敬岳，唐诗环，金津，等. 补肺活血胶囊对颗粒物致小鼠肺纤维化样变的影响［J］. 世界中西医结合杂志，2017，12（6）： 774-778.

JIN Y， TANG S H， JIN J， et al. Influence of pulmonary fibrosis in PM 2.5 model mice with Bufei Huoxue capsule［J］. World Journal of Integrated Traditional and Western Medicine， 2017， 12（6）： 774-778.

敬岳，金津，唐诗环，等. 中药补肺活血胶囊对细颗粒物所致小鼠肺损伤修复的影响［J］. 中国中医基础医学杂志，2019，25（2）： 171-174.

JIN Y， JIN J， TANG S H， et al. Effect of Bufei Huoxue capsule on the repair of lung injury induced by fine particulate matter in mice ［J］. Chinese Journal of Basic Medicine in Traditional Chinese Medicine， 2019，25（2）： 171-174.

孙世永. 补肺活血胶囊联合汉防己甲素片治疗煤工尘肺病人疗效观察［J］. 中医临床研究，2019，11（31）： 17-19.

SUN S Y. Observation on treating coal worker′s pneumoconiosis with the Bufei Huoxue capsule plus tetrandrine tablets［J］. Clinical Journal of Chinese Medicine， 2019， 11（31）： 17-19.

于向艳，耿立梅，候悦悦，等. 综合外治疗法联合补肺活血胶囊对支气管哮喘慢性持续期患者炎症因子及临床疗效的影响［J］. 中国新药杂志，2019，28（9）： 1094-1098.

YU X Y， GENG L M， HOU Y Y， et al. Effects of comprehensive external therapy combined with Bufei Huoxue capsule on inflammatory factors and clinical efficacy of patients with chronic bronchial asthma at chronic duration stage［J］. Chinese Journal of New Drugs， 2019， 28（9）： 1094-1098.

WANG X， YAN J， XU X， et al. Puerarin prevents LPS-induced acute lung injury via inhibiting inflammatory response ［J］. Microbial Pathogenesis， 2018， 118：170-176.

FENG G， SUN B， LI T Z. Daidzein attenuates lipopolysaccharide-induced acute lung injury via toll-like receptor 4/NF-kappaB pathway ［J］. International Immunopharmacology， 2015， 26（2）：392-400.

JIANG Y， YANG W， GUI S. Procyanidin B2 protects rats from paraquat-induced acute lung injury by inhibiting NLRP3 inflammasome activation ［J］. Immunobiology， 2018， 223（10）：555-561.

HU X， HUANG X. Alleviation of inflammatory response of pulmonary fibrosis in acute respiratory distress syndrome by puerarin via transforming growth factor （TGF-β1）［J］. Medical Science Monitor， 2019， 25：6523-6531.

LEE H J ， LEE S Y ， LEE M N， et al. Daidzein regulates secretion， production and gene expression of mucin from airway epithelial cells stimulated by proinflammatory factor and growth factor ［J］. Pulmonary Pharmacology and Therapeutics， 2011， 24（1）： 128-132.

SABA， KHAN S， PARVEZ S， et al. Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats ［J］. Food and Chemical Toxicology， 2013， 58：210-219.

NIKBAKHT J， HEMMATI A A， ARZI A， et al. Protective effect of gallic acid against bleomycin-induced pulmonary fibrosis in rats ［J］. Pharmacological Reports， 2015， 67（6）：1061-1067.

CHU C Q. How much have we learnt about the TNF family of cytokines？［J］. Cytokine， 2018， 101： 1-3.

HUANG W， AUGUST A. The signaling symphony： T cell receptor tunes cytokine-mediated T cell differentiation ［J］. Journal of Leukocyte Biolog， 2015， 97（3）： 477-485.

BIRUKOVA A A， MENG F， TIAN Y， et al. Prostacyclin post-treatment improves LPS-induced acute lung injury and endothelial barrier recovery via rap1［J］. Biochimica et Biophysica Acta， 2015， 1852（5）：778-791.

CAI Y， SUKHOVA G K， WONG H K， et al. Rap1 induces cytokine production in pro-inflammatory macrophages through NFκB signaling and is highly expressed in human atherosclerotic lesions ［J］. Cell Cycle， 2015， 14（22）：3580-3592.

张丽霞，张淑文. SARS恢复期肺纤维化中西医结合诊治的研究［J］. 中国中西医结合急救杂志，2004，11（5）： 268-270.

ZHANG L X， ZHANG S W. Study on treatment and diagnosis of integrated traditional Chinese and western medicine on lung fibrosis in recovery stage of SARS［J］. Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care， 2004， 11（5）： 268-270.

钟飞扬，张寒菲，王彬宸，等. 新型冠状病毒肺炎的CT影像学表现［J］. 武汉大学学报（医学版），2020，41（3）： 345-348.

ZHONG F Y， ZHANG H F， WANG B C， et al. CT findings in 2019 novel coronavirus disease （COVID-19） patients ［J］. Medical Journal of Wuhan University， 2020， 41（3）： 345-348.

MIAO H， YU Z， FEI X， et al. Role of PI3K/Akt/NF-κB and GSK-3β pathways in the rat model of cardiopulmonary bypass-related lung injury ［J］. Biomedicine & Pharmacotherapy， 2018， 106： 747-754.

XIE T， XU Q， WAN H， et al. Lipopolysaccharide promotes lung fibroblast proliferation through autophagy inhibition via activation of the PI3K-Akt-mTOR pathway ［J］. Laboratory Investigation， 2019， 99（5）： 625-633.

马爱平，高云周，兰文斌，等. PI3K/Akt/HIF-1α信号通路在博来霉素诱导小鼠肺纤维化中的作用机制研究［J］. 中国呼吸与危重监护杂志，2016，15（1）： 34-38.

MA A P， GAO Y Z， LAN W B， et al. The role of PI3K/Akt/HIF-1α signaling pathway in bleomycin-induced pulmonary fibrosis in mice［J］. Chinese Journal of Respiratory and Critical Care Medicine， 2016， 15（1）： 34-38.

ZHU Y ， TAN J ， XIE H ， et al. HIF-1α regulates EMT via the snail and β-catenin pathways in paraquat poisoning-induced early pulmonary fibrosis ［J］. Journal of Cellular and Molecular Medicine， 2016， 20（4）： 688-697.

IGNACIO N S， CONSTANZA N S， FERNANDA S O， et al. Transforming growth factor-beta and forkhead box O transcription factors as cardiac fibroblast regulators ［J］. BioScience Trends， 2017， 11（2）： 154-162.

ARTHAM S， GAO F， VERMA A， et al. Endothelial stromelysin1 regulation by the forkhead box-O transcription factors is crucial in the exudative phase of acute lung injury ［J］. Pharmacological Research， 2019， 141： 249-263.

IM J， HERGERT P， NHO R S. Reduced FoxO3a expression causes low autophagy in idiopathic pulmonary fibrosis fibroblasts on collagen matrices ［J］. American Journal of Physiology-Lung Cellular and Molecular Physiology， 2015， 309（6）： L552-561.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring the mechanism and function of Xiasangju in the treatment of xerophthalmia based on network pharmacology and experimental validation

Discovery of the active ingredients and the mechanism of action for the effects of Honghe Fujie Lotion on infection based on network pharmacology methods

Network pharmacology analysis of Compound Xueshuantong Capsule （CXC） in improving microcirculation

Mechanisms of “Astragalus membranaceus - Atractylodes macrocephala koidz” for the treatment of lung cancer based on network pharmacology

Related Author

Pan CHEN

Peibo LI

Minyi GUAN

Weiwei SU

Hongyu RAO

SUN Weiguang

WANG Yonggang

SU Weiwei

Related Institution

Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM， Guangdong Key Laboratory of Plant Resources， School of Life Sciences， Sun Yat-sen University

Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM / Guangdong Key Laboratory of Plant Resources / School of Life Sciences， Sun Yat-sen University

Guangzhou Baiyunshan Xingqun Pharmaceutical Co.， Ltd

School of Life Sciences， Sun Yat-sen University / Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM

Department of Oncology，Beijing Hospital of Traditional Chinese Medicine， Capital Medical University

Postal code：510275
Tel：020-84112585，84113223 Email：xuebaozr@mail.sysu.edu.cn
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰